After a bruising year, Aeterna Zentaris inks a $24M upfront US pact for growth hormone asset
Over the past year Aeterna Zentaris $AEZS has watched its lead drug go down in flames on a failed Phase III trial, gone back to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
